The role of molecular testing in pancreatic cancer.

Authors:
Zhen DB; Safyan RA; Konick EQ; Nguyen R; Prichard CC and 1 more

Journal:
Therap Adv Gastroenterol

Publication Year: 2023

DOI:
10.1177/17562848231171456

PMCID:
PMC10184226

PMID:
37197396

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Therap Adv Gastroenterol

Abbreviation: Therap Adv Gastroenterol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology & Hepatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and…
Li M; Chen S; Li S and 13 more (2024) - Transparency Score: 3/6
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in in…
Nigam GB; Chatten K; Sharara A and 6 more (2024) - Transparency Score: 4/6
Chemotherapy combined with targeted therapy and immunotherapy is an option in advanced biliary trac…
Ge P; Wu Y. (2024) - Transparency Score: 3/6
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with u…
Calafat M; Torres P; Tosca-Cuquerella J and 56 more (2024) - Transparency Score: 3/6
Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should <i>K…
Béchade D; Palmieri LJ; Bonhomme B and 7 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Zhen DB: research funding: Astra Zeneca, Bristol Myers Squibb, Cornerstone, Daiichi Sankyo, Eli Lilly, Legend, Merck, Roche; scientific advisory boards: Ipsen, QED Therapeutics, Cornerstone: Safyan RA: no conflicts of interest: Konnick E: no conflicts of interest: Nguyen R: no conflicts of interest: Pritchard C: no conflicts of interest: Chiorean EG: research funding AADi, Boehringer-Ingelheim, Clovis, Fibrogen, Merck, Lonza, BioMed Valley, Erasca, Roche, Novartis; scientific advisory boards: Astellas, Ipsen, Pfizer, G1 Therapeutics, Merus, BMS, Foundation One."

Evidence found in paper:

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025